HK Stock Market Move | GUSHENGTANG (02273) rose more than 5% and received intensive buying from star public funds, empowering operational efficiency through AI technology and OMO strategy.

GUSHENGTANG (02273) rose by more than 5%, reaching a 5.13% increase as of the press release, at HK$39.95, with a turnover of HK$131 million. On the news front, the latest information disclosed by the Hong Kong Stock Exchange shows that Ruoyuan Fund increased its holdings of GUSHENGTANG by 410,000 shares on February 26, at a price of HK$38.6889 per share, totaling approximately HK$15.8624 million. After the increase, the latest number of shares held is 14.7183 million shares, with a latest shareholding ratio of 6.04%. It is worth mentioning that as of December 30, 2024, major funds holding GUSHENGTANG include South Fund, E Fund, Huaxia Fund, Guolian Fund, Fuguo Fund, and Roubomai Fund. On February 19, Goldman Sachs FICC and Stock Division released the "China AI Medical Index" report, in which GUSHENGTANG was successfully included due to its advanced layout and innovative practice in the AI field. Earlier, GUSHENGTANG announced its access to DeepSeek. China Securities Co., Ltd. pointed out that in the future, the company will enhance diagnosis and operation efficiency through AI technology and OMO strategies; further enhance brand penetration through domestic and international expansion; and transform traditional Chinese medicine internal preparations through data intelligence. Currently, the company's valuation is at a historically low level, and it is optimistic about maintaining rapid growth in performance and gradually realizing value revaluation.